Five things for pharma marketers to know: Tuesday, October 4, 2016

Photo credit: Phil King/Creative Commons

1. Johnson & Johnson said one of its insulin pumps is at risk of being hacked and if that happened diabetes patients could be vulnerable to insulin overdose. The company sent warning letters to 114,000 patients in the U.S. and Canada who use the device with advice on how to fix the problem. (Fortune)

2. Japanese scientist Yoshinori Ohsumi won the 2016 Nobel Prize for his discoveries in autophagy, a process by which cells detoxify and recycle. Experts believe his discoveries may lead to advances in treatments for Alzheimer's disease, Parkinson's disease, and cancer. (WSJ)

3. Merrimack CEO Robert Mulroy left the company and chairman Gary Crocker was named interim chief until the drugmaker finds a permanent replacement. The company, which markets pancreatic cancer drug Onivyde, also said it plans to cut 22% of its workforce. (WSJ)

4. Sarepta Therapeutics partnered with Summit Therapeutics to license Summit's Duchenne muscular dystrophy drug. The deal gives Sarepta access to Summit's utrophin modulator pipeline, which includes its leading experimental Duchenne therapy, in Europe, Turkey, and several other countries. (Reuters)

5. Roche said its lung-cancer treatment, Alecensa, its anaplastic lymphoma kinase inhibitor, received its second Breakthrough Therapy designation. The designation is for the treatment of adult patients with advanced ALK-positive non-small cell lung cancer. (Reuters)